EP0871643A4 - Anti-viral guanosine-rich oligonucleotides - Google Patents

Anti-viral guanosine-rich oligonucleotides

Info

Publication number
EP0871643A4
EP0871643A4 EP96930490A EP96930490A EP0871643A4 EP 0871643 A4 EP0871643 A4 EP 0871643A4 EP 96930490 A EP96930490 A EP 96930490A EP 96930490 A EP96930490 A EP 96930490A EP 0871643 A4 EP0871643 A4 EP 0871643A4
Authority
EP
European Patent Office
Prior art keywords
rich oligonucleotides
guanosine
viral
viral guanosine
oligonucleotides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP96930490A
Other languages
German (de)
French (fr)
Other versions
EP0871643A1 (en
Inventor
Robert F Rando
Susan Fennewald
Joseph G Zendegui
Joshua O Ojwang
Michael E Hogan
Yves Pommier
Abhijit Mazumder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aronex Pharmaceuticals Inc
Original Assignee
Aronex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/535,168 external-priority patent/US6184369B1/en
Application filed by Aronex Pharmaceuticals Inc filed Critical Aronex Pharmaceuticals Inc
Publication of EP0871643A1 publication Critical patent/EP0871643A1/en
Publication of EP0871643A4 publication Critical patent/EP0871643A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1133—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against herpetoviridae, e.g. HSV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/15—Nucleic acids forming more than 2 strands, e.g. TFOs
    • C12N2310/151—Nucleic acids forming more than 2 strands, e.g. TFOs more than 3 strands, e.g. tetrads, H-DNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/18—Type of nucleic acid acting by a non-sequence specific mechanism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/335—Modified T or U
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
EP96930490A 1995-07-19 1996-07-17 Anti-viral guanosine-rich oligonucleotides Withdrawn EP0871643A4 (en)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US601505 1984-04-18
US08/535,168 US6184369B1 (en) 1993-04-23 1994-04-25 Anti-viral guanosine-rich oligonucleotides
US150595P 1995-07-19 1995-07-19
US1368896P 1996-03-19 1996-03-19
US61368 1996-03-19
US1400796P 1996-03-25 1996-03-25
US64007 1996-03-25
US1571496P 1996-04-17 1996-04-17
US15714 1996-04-17
US1627196P 1996-04-23 1996-04-23
PCT/US1996/011786 WO1997003997A1 (en) 1995-07-19 1996-07-17 Anti-viral guanosine-rich oligonucleotides
US5351 1998-01-09
US16271 2001-11-02

Publications (2)

Publication Number Publication Date
EP0871643A1 EP0871643A1 (en) 1998-10-21
EP0871643A4 true EP0871643A4 (en) 2000-12-06

Family

ID=27555390

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96930490A Withdrawn EP0871643A4 (en) 1995-07-19 1996-07-17 Anti-viral guanosine-rich oligonucleotides

Country Status (4)

Country Link
EP (1) EP0871643A4 (en)
AU (1) AU725936B2 (en)
CA (1) CA2227867A1 (en)
WO (1) WO1997003997A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6288042B1 (en) 1993-04-23 2001-09-11 Aronex Pharmaceuticals, Inc. Anti-viral guanosine-rich tetrad forming oligonucleotides
US5912332A (en) * 1996-07-26 1999-06-15 Hybridon, Inc. Affinity-based purification of oligonucleotides using soluble multimeric oligonucleotides
PL334197A1 (en) * 1996-12-27 2000-02-14 Icn Pharmaceuticals Oligonucleotidic aptamers of high g content and methods of modulating immunilogical response
CA2279488A1 (en) * 1997-02-04 1998-08-06 Aronex Pharmaceuticals, Inc. Anti-viral guanosine-rich tetrad forming oligonucleotides
JP2009511023A (en) * 2005-10-06 2009-03-19 ユニバーシティー、オブ、デラウェア G-rich polynucleotide for the treatment of Huntington's disease

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994008053A1 (en) * 1992-09-29 1994-04-14 Isis Pharmaceuticals, Inc. Oligonucleotides having a conserved g4 core sequence
WO1994025037A1 (en) * 1993-04-23 1994-11-10 Triplex Pharmaceutical Corporation Anti-viral guanosine-rich oligonucleotides

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3687808A (en) * 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US4388306A (en) * 1980-06-04 1983-06-14 Merck & Co., Inc. Pharmaceutical composition comprising modified polyriboinosinic-polyribocytidylic acid, for induction of interferon in primates
FR2567892B1 (en) * 1984-07-19 1989-02-17 Centre Nat Rech Scient NOVEL OLIGONUCLEOTIDES, THEIR PREPARATION PROCESS AND THEIR APPLICATIONS AS MEDIATORS IN DEVELOPING THE EFFECTS OF INTERFERONS
GB8717430D0 (en) * 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5176996A (en) * 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5397702A (en) * 1989-03-06 1995-03-14 The Regents Of The University Of California Assay for and treatment of autoimmune diseases
US5075217A (en) * 1989-04-21 1991-12-24 Marshfield Clinic Length polymorphisms in (dC-dA)n ·(dG-dT)n sequences
US5173426A (en) * 1989-10-06 1992-12-22 Yale University DNAs encoding genetically engineered low oxygen affinity mutants of human hemoglobin
DE4216134A1 (en) * 1991-06-20 1992-12-24 Europ Lab Molekularbiolog SYNTHETIC CATALYTIC OLIGONUCLEOTIDE STRUCTURES

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994008053A1 (en) * 1992-09-29 1994-04-14 Isis Pharmaceuticals, Inc. Oligonucleotides having a conserved g4 core sequence
WO1994025037A1 (en) * 1993-04-23 1994-11-10 Triplex Pharmaceutical Corporation Anti-viral guanosine-rich oligonucleotides

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BISHOP JEFFREY S ET AL: "Intramolecular G-quartet motifs confer nuclease resistance to a potent anti-HIV oligonucleotide.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 271, no. 10, 8 March 1996 (1996-03-08), pages 5698 - 5703, XP002148821, ISSN: 0021-9258 *
FUJIHASHI T ET AL: "ANTIVIRAL ACTION OF OLIGODEOXYGUANYLIC ACIDS AGAINST HUMAN IMMUNODEFICIENCY VIRUS TYPE I", AIDS RESEARCH AND HUMAN RETROVIRUSES, vol. 11, no. 4, April 1995 (1995-04-01), pages 461 - 471, XP002068239, ISSN: 0889-2229 *
MAZUMDER ABHIJIT ET AL: "Inhibition of the human immunodeficiency virus type 1 integrase by guanosine quartet structures.", BIOCHEMISTRY, vol. 35, no. 43, 29 October 1996 (1996-10-29), pages 13762 - 13771, XP002148822, ISSN: 0006-2960 *
MOUSCADET JEAN-FRANCOIS ET AL: "Triplex-mediated inhibition of HIV DNA integration in vitro.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 269, no. 34, 1994, pages 21635 - 21638, XP002148820, ISSN: 0021-9258 *
OJWANG JOSHUA O ET AL: "T30177, an oligonucleotide stabilized by an intramolecular guanosine, Octet, is a potent inhibitor of laboratory strains, and clinical isolates of human immunodeficiency virus type 1.", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 39, no. 11, November 1995 (1995-11-01), pages 2426 - 2435, XP000946679, ISSN: 0066-4804 *
RANDO R F ET AL: "SUPPRESSION OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 ACTIVITY IN VITRO BY OLIGONUCLEOTIDES WHICH FORM INTRAMOLECULAR TETRADS", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 270, no. 4, 27 January 1995 (1995-01-27), pages 1754 - 1760, XP002068457, ISSN: 0021-9258 *
See also references of WO9703997A1 *

Also Published As

Publication number Publication date
EP0871643A1 (en) 1998-10-21
AU6950696A (en) 1997-02-18
CA2227867A1 (en) 1997-02-06
AU725936B2 (en) 2000-10-26
WO1997003997A1 (en) 1997-02-06

Similar Documents

Publication Publication Date Title
EP0699071A4 (en) Anti-viral guanosine-rich oligonucleotides
IL122377A0 (en) Anti-viral compounds
IL118545A0 (en) Anti-viral compounds
EP0871643A4 (en) Anti-viral guanosine-rich oligonucleotides
DE59602888D1 (en) Breitstreckaggregat
DE59602030D1 (en) Zellige polyurethan-elastomere
DE59602283D1 (en) Inchbremseinrichtung
DE59505396D1 (en) Handhobelmaschine
EP1021674A4 (en) Formed ragglestick
GB9518539D0 (en) Complex
AP9600802A0 (en) Libricant
DE59600830D1 (en) Breitstrahldüse
GB9515308D0 (en) Complex
GB2307038B (en) Baffle
GB9512815D0 (en) Anti-viral compounds
AU1105P (en) DALESE Metrosideros excelsus
HU9500211V0 (en) Small shording section
PL103537U1 (en) Shape
ZA969476B (en) Complex
IL113924A0 (en) Mechanotherapy complex
ZA967806B (en) Forming solutions
GB9500391D0 (en) Forming solutions
AU124982S (en) Snow - bike
AU125614S (en) Billycart
AU125678S (en) Sandboard

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19980216

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20001018

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20030811

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20050508